On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Alzheimer’s Disease Market Growth Driven by Innovative Developments Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595

  • Companies like INmune Bio are advancing the development of innovative treatment methods
  • INmune’s lead drug candidate, XPro1595, works by targeting neuroinflammation, one of the causes of Alzheimer’s
  • XPro1595 is set to undergo a phase I clinical trial in the summer of 2019 with a goal of measuring traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer’s

The global market for Alzheimer’s disease (AD) treatments is forecast to double in value by 2023, reaching $4.9 billion, according to GlobalData research (http://ibn.fm/8ZqMy). The growth rate has been estimated at 10.5 percent for the forecast period.

The increasing prevalence of Alzheimer’s disease, advanced diagnostic capabilities and technological advances are all expected to contribute to the future growth. Companies like INmune Bio Inc. (NASDAQ: INMB) are working hard on such technological and pharmaceutical advances. The clinical-stage immunology company is developing novel therapies that affect a specific part of the patient’s immune system to produce a disease-fighting response.

The company’s drug candidate, XPro1595, targets neuroinflammation – one of the causes of AD.

In June 2019, Pfizer researchers announced an important discovery highlighting the connection between neuroinflammation and AD. Medications that work in a manner similar to XPro1595 reduce the risk of AD development by as much as 64 percent. The Pfizer research confirms previous studies on the topic. A 2016 analysis of 8.5 million individuals showed that patients given medications suppressing neuroinflammation were less likely to develop AD than controls (http://ibn.fm/FCxY8).

An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which it could be used to offer reliable AD treatments have both been overlooked. Numerous inflammatory markers are found in AD patients and several studies establish a link between chronic inflammation and the development of AD.

XPro1595 works by targeting the microglial immune cells of the brain. These cells are activated in many AD patients. They cause neuroinflammation that kills nerve cells and promotes synaptic dysfunction. Combined, these two effects lead to dementia in people with AD.

XPro1595 is currently undergoing strenuous testing. A three-month, phase I trial will involve 18 patients and will be carried out in the summer of 2019. Through the trial, INmune Bio will measure traditional and novel biomarkers of inflammation in people with mild to moderate AD. The Alzheimer’s Association is supporting the trial financially through the provision of a $1 million grant.

Such clinical work is of especially high importance due to AD developments over the past few years. The prevalence of AD doubles every five years, a report titled ‘Alzheimer’s Disease – Competitive Landscape and Market’ suggests (http://ibn.fm/vnczv). The prevalence of the condition has reached 40 percent of the 90-94 age group. The World Health Organization (WHO) reports that AD prevalence is also set to increase by in those aged 65 or older, from 6.8 percent in 2000 to 16.2 percent by 2050. The prevalence of dementia as a consequence is anticipated to increase from 24 million cases in 2005 to 81 million cases in 2040.

Based in La Jolla, California, INmune Bio is a diversified clinical-stage biotechnology company working to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. With its programs in oncology and neurodegenerative disease, the company offers intriguing investment opportunities.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered